Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorArulananda, Surein-
dc.contributor.authorThapa, Bibhusal-
dc.contributor.authorWalkiewicz, Marzena-
dc.contributor.authorZapparoli, Giada V-
dc.contributor.authorWilliams, David S-
dc.contributor.authorDobrovic, Alexander-
dc.contributor.authorJohn, Thomas-
dc.identifier.citationJournal of Thoracic Oncology 2018; 13(10): 1588-1594en
dc.description.abstractMalignant pleural mesothelioma is an aggressive malignancy with limited systemic therapy options. Promising results have been reported with use of anti-PD-1 therapy, however it appears to be confined to a subgroup of patients. Microsatellite instability (MSI) results from the inactivation of DNA mismatch repair genes and results in a high tumour mutational burden, a phenomenon that has not been seen with mesothelioma. MSI and protein absence have been shown to correlate in colorectal cancer, such that most centres have adopted IHC to screen for MSI-high colorectal cancers. We profiled a large mesothelioma cohort to determine the rate of negative immunohistochemistry for the four common mismatch repair proteins. A tissue microarray comprising 335 patients with malignant pleural mesothelioma were used. Immunohistochemistry (IHC) for the four common mismatch repair proteins (MLH1, PMS2, MSH2 and MSH6) was performed. PD-L1 IHC staining with the E1L3N clone was also performed. DNA was isolated from IHC equivocal samples and analysed for microsatellite instability using the Promega MSI Analysis System, Version 1.2. Of 335 patients profiled, 329 had intact mismatch repair proteins by immunohistochemistry. Six samples with absent mismatch repair protein immunohistochemistry analysis were analysed for MSI and confirmed to be negative. Of the six IHC+ samples, five were absent for PD-L1 staining and one sample had more than 5% staining. In this large retrospective series, we were unable to identify any malignant pleural mesothelioma patients with microsatellite instability. Response to anti-PD-1 based immunotherapy may be driven by other mechanisms.en
dc.subjectMalignant pleural mesotheliomaen
dc.subjectmicrosatellite instabilityen
dc.subjectmismatch repair proteinen
dc.titleMismatch repair protein defects and microsatellite instability in malignant pleural mesothelioma.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Thoracic Oncologyen
dc.identifier.affiliationOlivia Newton-John Cancer Research Instituteen
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australiaen
dc.identifier.affiliationTranslational Genomics and Epigenomics Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Pathology, University of Melbourne, Parkville, Victoria, Australiaen
dc.identifier.affiliationMedical Oncologyen
dc.identifier.affiliationOlivia Newton-John Cancer Wellness and Research Centreen
dc.type.austinJournal Article-, Alexander
item.fulltextNo Fulltext-
item.openairetypeJournal Article- Newton-John Cancer Research Institute- Surgery- Newton-John Cancer Research Institute- Newton-John Cancer Research Institute- (University of Melbourne)- Newton-John Cancer Research Institute- Oncology- Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Jun 22, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.